Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies

Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies

Chapter 1: Chapter 1: NCCN Guidelines for Immunotherapy in the treatment of Metastatic Endometrial Cancer

4 chapters
Play All
ReachMD Healthcare Image
Media formats available:
Program chapters
  • Overview

    The recent addition of immunotherapy to our armamentarium for endometrial and cervical cancer has shifted the treatment landscape. Listen in as Drs. Robert Coleman, Susana Campos, and Domenica Lorusso discuss innovations in immunotherapy and what role antibody-drug conjugates (ADCs) play in this setting.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Robert L. Coleman, MD, FACOG, FACS
    Chief Scientific Officer,
    US Oncology Research
    Houston, TX

    Advisory or Consulting Fees: Abbvie, Agenus, Alkermes, AstraZeneca, Clovis Oncology, Deciphera, Genelux, Genmab, GlaxoSmithKline, Immunogen, Janssen, Merck, Novocure, OncoQuest, OncXerna, Onxeo, Regeneron, Roche/Genentech, VBL Therapeutics
    Grants or contracts: AstraZeneca, Clovis, Genelux, Genmab, Merck, Immunogen, Janssen, Roche/Genentech
    Commercial Interest Speakers Bureau: AstraZeneca, Clovis, Merck, Roche/Genentech


    Susana Campos, MD, MPH
    Assistant Professor of Medicine
    Dana Farber Cancer Institute
    Harvard Medical School
    Boston, MA

    Consulting Fees: AstraZeneca, Eisai, GlaxoSmithKline, and Merck

    Domenica Lorusso, MD, PhD
    Associate Professor of Gynecologic Oncology
    Catholic University of Rome
    Rome, Italy

    Advisor or consultant for: Agenus, Amgen, AstraZeneca, Clovis Oncology, Genmab, GlaxoSmithKline, Immunogen, Merck Serono, Merck Sharp & Dohme, Novartis, PharmaMar
    Speakers Bureau: Clovis Oncology, GlaxoSmithKline
    Grants for clinical research from: Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme, PharmaMar

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Examine the latest clinical data of immune-oncologic agents and combinations for advanced endometrial cancer
    • Review the latest clinical data of immune-oncologic agents for advanced cervical cancer
    • Apply evidence-based recommendations to select optimal immune-oncologic therapies for patients with cervical cancer
  • Target Audience

    This activity is designed to meet the educational needs of gynecologic oncologists, medical oncologists, obstetrician-gynecologists, pathologists, nurses, pharmacists, and other oncology HCPs involved in the treatment of patients with gynecologic cancers globally.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), the National Comprehensive Cancer Network® (NCCN®), and La Fundación ECO (ECO Foundation). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this Panel Discussion activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until November 30, 2023. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for .50 contact hours/.05 CEUs by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is JA0006235-9999-22-055-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by independent educational grants from Merck, Genmab and Seagen Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free